In Nov. 2022, the U.S. nonprofit Multidisciplinary Association for Psychedelic research (MAPS) declared that it had finished a next phase-3 demo on MDMA as being a treatment method for PTSD—a move commonly seen as the https://oisidars493104.hyperionwiki.com/user